Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy

Cancer Research

Volumn 74, Issue 1, 2014, Pages 153-161

  Mok, Stephen ^a   Koya, Richard C ^g,h   Tsui, Christopher ^e   Xu, Jingying ^a   Robert, Lídia ^e   Wu, Lily ^a,d   Graeber, Thomas G ^a,b,d,e   West, Brian L ^f   Bollag, Gideon ^f   Ribas, Antoni ^a,b,c,d,e,h  

^a Department of Molecular and Medical Pharmacology ^*  (India)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Division of Surgical Oncology   (United States)

^d Institute for Molecular Medicine   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f PLEXXIKON INC   (United States)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

^h Division of Hematology Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CLODRONIC ACID; COLONY STIMULATING FACTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PLX 3397; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL INFILTRATION; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; IMMUNE RESPONSE; IN VIVO STUDY; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ASSOCIATED MYELOID CELL;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; IMMUNOTHERAPY, ADOPTIVE; MELANOMA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTEIN KINASE INHIBITORS; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR;

EID: 84892738557     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1816     Document Type: Article

References (27)

1. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
2. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565-70.
3. Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res 2012;72:3125-30.
4. Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Collado AX, Moughon DL, et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 2010;115:1461-71.
5. Tarhini AA, Butterfield LH, Shuai Y, Gooding WE, Kalinski P, Kirkwood JM. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-alpha or TLR-9 agonist and GM-CSF with peptide vaccination. J Immunother 2012;35: 702-10.
6. Dai XM, Ryan GR, Hapel AJ, Dominguez MG, Russell RG, Kapp S, et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 2002;99:111-20.
7. Li J, Chen K, Zhu L, Pollard JW. Conditional deletion of the colony stimulating factor-1 receptor (c-fms proto-oncogene) in mice. Genesis 2006;44:328-35.
8. Koya RC, Mok S, Otte N, Blacketor KJ, Comin-Anduix B, Tumeh PC, et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res 2012;72:3928-37.
9. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007;445:851-7.
10. Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest 2013;123:1371-81.
11. Chitu V, Nacu V, Charles JF, Henne WM, McMahon HT, Nandi S, et al. PSTPIP2 deficiency in mice causes osteopenia and increased differentiation of multipotent myeloid precursors into osteoclasts. Blood 2012;120:3126-35.
12. Coniglio SJ, Eugenin E, Dobrenis K, Stanley ER, West BL, Symons MH, et al. Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol Med 2012;18:519-27.
13. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011;1:54-67.
14. Xu J, Escamilla J, Mok S, David J, Priceman SJ, West BL, et al. Abrogating the protumorigenic influences of tumor-infiltrating myeloid cells by CSF1R signaling blockade improves the efficacy of radiotherapy in prostate cancer. Cancer Res 2013;73:2782-94.
15. Koya RC, Mok S, Comin-Anduix B, Chodon T, Radu CG, Nishimura MI, et al. Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses. Proc Natl Acad Sci U S A 2010;107:14286-91.
16. Vo DD, Prins RM, Begley JL, Donahue TR, Morris LF, Bruhn KW, et al. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res 2009;69:8693-9.
17. He Y, Rhodes SD, Chen S, Wu X, Yuan J, Yang X, et al. c-Fms signaling mediates neurofibromatosis Type-1 osteoclast gain-in-functions. PLoS One 2012;7:e46900.
18. McArthur GA, Ribas A. Targeting oncogenic drivers and the immune system in melanoma. J Clin Oncol 2013;31:499-506.
19. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012;12:253-68.
20. Srivastava MK, Zhu L, Harris-White M, Kar U, Huang M, Johnson MF, et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One 2012;7:e40677.
21. Gros A, Turcotte S, Wunderlich JR, Ahmadzadeh M, Dudley ME, Rosenberg SA. Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clin Cancer Res 2012;18:5212-23.
22. Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science 2008;320:807-11.
23. Wei S, Nandi S, Chitu V, Yeung YG, Yu W, Huang M, et al. Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells. J Leukoc Biol 2010;88: 495-505.
24. Sawanobori Y, Ueha S, Kurachi M, Shimaoka T, Talmadge JE, Abe J, et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008;111:5457-66.
25. Li X, Loberg R, Liao J, Ying C, Snyder LA, Pienta KJ, et al. A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res 2009;69:1685-92.
26. Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res 2010;70: 5679-85.
27. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010; 120:694-705.